Clinical Trials · NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,000
- Start date
- Jul 2023
- Locations
- 98 sites, 8 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight